Envveno Medical Corp (NVNO)

$4.07 -0.10 (-2.40%)
Market Cap 71.37M
Revenue (ttm) 0.00
Net Income (ttm) -21.82M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 108,200
Avg Vol 101,130
Day's Range N/A - N/A
Shares Out 17.54M
Stochastic %K 32%
Beta 0.92
Analysts Strong Sell
Price Target $12.50

Company Profile

enVVeno Medical Corporation, a clinical-stage medical device company, focuses on the development of bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous disease. The company's lead product is the VenoValve, a replacement venous valve for the treatment of venous chronic venous insufficiency. Its VenoValve implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The company also develops e...

Industry: Medical Devices
Sector: Healthcare
Phone: 949 261 2900
Address:
70 Doppler, Irvine, United States
ELONandTRUMP
ELONandTRUMP Jun. 29 at 4:25 PM
$NVNO Im expecting a huge increase in the price when FDA hits if not I'm probably moving on this stock is a joke.
1 · Reply
Rasta747
Rasta747 Jun. 29 at 3:48 PM
$NVNO This has become a very long play. Much longer than I expected. Can't move. Continue to wait.
0 · Reply
Thorne321
Thorne321 Jun. 27 at 4:41 PM
$NVNO there's been heavy insider buys
1 · Reply
FelixH86
FelixH86 Jun. 27 at 3:53 PM
$NVNO no Action on a friday?..:-]
0 · Reply
ELONandTRUMP
ELONandTRUMP Jun. 26 at 8:05 PM
$NVNO This will start to get into the double digits in the coming months you will be fine but the CEO is annoying.
1 · Reply
FelixH86
FelixH86 Jun. 26 at 5:23 PM
$NVNO i am in..added 1200 shares...go luck..
0 · Reply
Rasta747
Rasta747 Jun. 26 at 4:46 PM
$NVNO
0 · Reply
Icemanja
Icemanja Jun. 26 at 4:22 PM
$NVNO enVVe GLP study results, including both long-term and short-term subjects, should be released soon. Successful completion of all planned Implants for the enVVe GLP Study was completed on Dec 16th. Its a 6 month study for IDE application. EnVVe is the Non-surgical product line.
0 · Reply
ELONandTRUMP
ELONandTRUMP Jun. 25 at 5:03 PM
$NVNO
0 · Reply
BigGreenCandle
BigGreenCandle Jun. 25 at 3:48 PM
$NVNO If I put in a sell order for $33, how long until it gets filled? Or should I hold some back for the double top at $86? Can we try a moon shot for a change?
1 · Reply
Latest News on NVNO
Positive Interim 2-Year Data from enVVeno Medical's VenoValve Pivotal Study to be Presented Today at the Society for Vascular Surgery (SVS) 2025 Vascular Annual Meeting

Jun 6, 2025, 8:05 AM EDT - 23 days ago

Positive Interim 2-Year Data from enVVeno Medical's VenoValve Pivotal Study to be Presented Today at the Society for Vascular Surgery (SVS) 2025 Vascular Annual Meeting

enVVeno Medical Appoints Jennifer Bright as Chief Financial Officer

May 19, 2025, 8:05 AM EDT - 5 weeks ago

enVVeno Medical Appoints Jennifer Bright as Chief Financial Officer

Three-Year VenoValve(R) First-in-Human Trial Data Published in the Annals of Vascular Surgery

May 13, 2025, 8:45 AM EDT - 6 weeks ago

Three-Year VenoValve(R) First-in-Human Trial Data Published in the Annals of Vascular Surgery

enVVeno Medical Reports First Quarter 2025 Financial Results and Reiterates Progress Toward VenoValve FDA Decision Expected in 2H24

May 1, 2025, 8:05 AM EDT - 2 months ago

enVVeno Medical Reports First Quarter 2025 Financial Results and Reiterates Progress Toward VenoValve FDA Decision Expected in 2H24

VenoValve to be Featured During Presentation at the 47th Annual Charing Cross Symposium

Apr 23, 2025, 8:00 AM EDT - 2 months ago

VenoValve to be Featured During Presentation at the 47th Annual Charing Cross Symposium

enVVeno Medical to Participate in a Live Virtual Investor Closing Bell Segment

Apr 16, 2025, 8:30 AM EDT - 2 months ago

enVVeno Medical to Participate in a Live Virtual Investor Closing Bell Segment

The Impact of the VenoValve(R) on Patients with Primary and Secondary Chronic Venous Insufficiency (CVI) to be Presented at the Society for Clinical Vascular Surgery 52nd Annual Symposium

Mar 31, 2025, 9:00 AM EDT - 3 months ago

The Impact of the VenoValve(R) on Patients with Primary and Secondary Chronic Venous Insufficiency (CVI) to be Presented at the Society for Clinical Vascular Surgery 52nd Annual Symposium

enVVeno Medical Reports Fourth Quarter and Year-End 2024 Financial Results and Progress Towards VenoValve FDA Approval Expected in 2H25

Feb 28, 2025, 8:00 AM EST - 4 months ago

enVVeno Medical Reports Fourth Quarter and Year-End 2024 Financial Results and Progress Towards VenoValve FDA Approval Expected in 2H25

enVVeno Medical Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Feb 19, 2025, 9:00 AM EST - 4 months ago

enVVeno Medical Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

One-Year Data from the VenoValve(R) U.S. Pivotal Trial Highlighting Impact on Patients' Quality of Life (QOL) to be Presented Today at the 37th Annual Meeting of the American Venous Forum

Feb 19, 2025, 8:45 AM EST - 4 months ago

One-Year Data from the VenoValve(R) U.S. Pivotal Trial Highlighting Impact on Patients' Quality of Life (QOL) to be Presented Today at the 37th Annual Meeting of the American Venous Forum

Interim Two-Year Follow-Up Data from the VenoValve(R) U.S. Pivotal Trial to be Presented Today at the VESS 2025 Annual Winter Meeting

Feb 7, 2025, 9:00 AM EST - 5 months ago

Interim Two-Year Follow-Up Data from the VenoValve(R) U.S. Pivotal Trial to be Presented Today at the VESS 2025 Annual Winter Meeting

enVVeno Medical Successfully Completes Final Wave of Implants in Pre-Clinical GLP Study for enVVe

Dec 16, 2024, 8:50 AM EST - 6 months ago

enVVeno Medical Successfully Completes Final Wave of Implants in Pre-Clinical GLP Study for enVVe

enVVeno Medical Highlights Successful 2024 VEITH Symposium with Launch of Recap Website

Nov 27, 2024, 8:30 AM EST - 7 months ago

enVVeno Medical Highlights Successful 2024 VEITH Symposium with Launch of Recap Website

enVVeno Medical to Present Definitive One Year Data from the VenoValve U.S. Pivotal Trial Today at the 51st Annual VEITH Symposium

Nov 20, 2024, 8:30 AM EST - 7 months ago

enVVeno Medical to Present Definitive One Year Data from the VenoValve U.S. Pivotal Trial Today at the 51st Annual VEITH Symposium

enVVeno Medical Submits the VenoValve PMA Application Seeking FDA Approval

Nov 19, 2024, 8:15 AM EST - 7 months ago

enVVeno Medical Submits the VenoValve PMA Application Seeking FDA Approval

Hancock Jaffe to Participate in the Duologue Series Virtual Webinar Hosted by Ladenburg Thalmann

Sep 24, 2021, 9:00 AM EDT - 4 years ago

Hancock Jaffe to Participate in the Duologue Series Virtual Webinar Hosted by Ladenburg Thalmann

Hancock Jaffe To Rebrand As enVVeno Medical

Sep 22, 2021, 7:09 AM EDT - 4 years ago

Hancock Jaffe To Rebrand As enVVeno Medical

Hancock Jaffe Announces Corporate Rebranding to Reflect Prioritization of its Development Pipeline on Venous Disease Programs

Sep 21, 2021, 4:00 PM EDT - 4 years ago

Hancock Jaffe Announces Corporate Rebranding to Reflect Prioritization of its Development Pipeline on Venous Disease Programs

Hancock Jaffe to Host Corporate Update Conference Call and Webcast on September 21, 2021

Sep 15, 2021, 8:05 AM EDT - 4 years ago

Hancock Jaffe to Host Corporate Update Conference Call and Webcast on September 21, 2021

Hancock Jaffe Laboratories: Developing Nature-Mimetic Bioprosthetics

Sep 8, 2021, 7:43 PM EDT - 4 years ago

Hancock Jaffe Laboratories: Developing Nature-Mimetic Bioprosthetics

Hancock Jaffe Laboratories Announces $20 Million Registered Direct Offering Priced At-the-Market Under NASDAQ Rules

Sep 7, 2021, 8:05 AM EDT - 4 years ago

Hancock Jaffe Laboratories Announces $20 Million Registered Direct Offering Priced At-the-Market Under NASDAQ Rules

Hancock Jaffe Highlights Two-Year Data For Venous Insufficiency Valve

Aug 19, 2021, 11:49 AM EDT - 4 years ago

Hancock Jaffe Highlights Two-Year Data For Venous Insufficiency Valve

Hancock Jaffe Presents New Positive Two-Year VenoValve Data at the Society for Vascular Surgery Annual Meeting

Aug 19, 2021, 8:00 AM EDT - 4 years ago

Hancock Jaffe Presents New Positive Two-Year VenoValve Data at the Society for Vascular Surgery Annual Meeting

Hancock Jaffe Stock Surges On FDA Breakthrough Designation For Its Venous Insufficiency Device

Aug 3, 2021, 8:58 AM EDT - 4 years ago

Hancock Jaffe Stock Surges On FDA Breakthrough Designation For Its Venous Insufficiency Device

FDA Grants Breakthrough Device Designation Status for Hancock Jaffe's VenoValve

Aug 3, 2021, 8:05 AM EDT - 4 years ago

FDA Grants Breakthrough Device Designation Status for Hancock Jaffe's VenoValve

Hancock Jaffe to Present at the Ladenburg Thalmann 2021 Healthcare Conference

Jul 8, 2021, 9:05 AM EDT - 4 years ago

Hancock Jaffe to Present at the Ladenburg Thalmann 2021 Healthcare Conference

Hancock Jaffe Principal Investigator Dr. Jorge Hernando Ulloa Presents VenoValve One Year First-In-Human Data at Charing Cross International Symposium

Apr 23, 2021, 12:40 PM EDT - 4 years ago

Hancock Jaffe Principal Investigator Dr. Jorge Hernando Ulloa Presents VenoValve One Year First-In-Human Data at Charing Cross International Symposium

First U.S. Patent Issues on Hancock Jaffe VenoValve

Apr 7, 2021, 1:40 PM EDT - 4 years ago

First U.S. Patent Issues on Hancock Jaffe VenoValve

Hancock Jaffe Receives IDE Approval To Begin VenoValve U.S. Pivotal Trial

Apr 5, 2021, 7:30 AM EDT - 4 years ago

Hancock Jaffe Receives IDE Approval To Begin VenoValve U.S. Pivotal Trial

Hancock Jaffe Submits IDE Application to FDA for VenoValve U.S. Pivotal Trial

Mar 8, 2021, 8:30 AM EST - 4 years ago

Hancock Jaffe Submits IDE Application to FDA for VenoValve U.S. Pivotal Trial

Hancock Jaffe Concludes Successful VenoValve Pre-IDE Meeting with FDA

Jan 12, 2021, 8:30 AM EST - 4 years ago

Hancock Jaffe Concludes Successful VenoValve Pre-IDE Meeting with FDA

Hancock Jaffe Announces Executive Promotions

Dec 30, 2020, 4:15 PM EST - 4 years ago

Hancock Jaffe Announces Executive Promotions

Hancock Jaffe Deemed Compliant With All NASDAQ Continued Listing Requirements

Dec 21, 2020, 8:30 AM EST - 4 years ago

Hancock Jaffe Deemed Compliant With All NASDAQ Continued Listing Requirements

ELONandTRUMP
ELONandTRUMP Jun. 29 at 4:25 PM
$NVNO Im expecting a huge increase in the price when FDA hits if not I'm probably moving on this stock is a joke.
1 · Reply
Rasta747
Rasta747 Jun. 29 at 3:48 PM
$NVNO This has become a very long play. Much longer than I expected. Can't move. Continue to wait.
0 · Reply
Thorne321
Thorne321 Jun. 27 at 4:41 PM
$NVNO there's been heavy insider buys
1 · Reply
FelixH86
FelixH86 Jun. 27 at 3:53 PM
$NVNO no Action on a friday?..:-]
0 · Reply
ELONandTRUMP
ELONandTRUMP Jun. 26 at 8:05 PM
$NVNO This will start to get into the double digits in the coming months you will be fine but the CEO is annoying.
1 · Reply
FelixH86
FelixH86 Jun. 26 at 5:23 PM
$NVNO i am in..added 1200 shares...go luck..
0 · Reply
Rasta747
Rasta747 Jun. 26 at 4:46 PM
$NVNO
0 · Reply
Icemanja
Icemanja Jun. 26 at 4:22 PM
$NVNO enVVe GLP study results, including both long-term and short-term subjects, should be released soon. Successful completion of all planned Implants for the enVVe GLP Study was completed on Dec 16th. Its a 6 month study for IDE application. EnVVe is the Non-surgical product line.
0 · Reply
ELONandTRUMP
ELONandTRUMP Jun. 25 at 5:03 PM
$NVNO
0 · Reply
BigGreenCandle
BigGreenCandle Jun. 25 at 3:48 PM
$NVNO If I put in a sell order for $33, how long until it gets filled? Or should I hold some back for the double top at $86? Can we try a moon shot for a change?
1 · Reply
MakeSomeMoneyToday
MakeSomeMoneyToday Jun. 24 at 5:53 PM
$NVNO https://evtoday.com/news/envvenos-venovalve-for-cvi-evaluated-in-pivotal-study-2-year-interim-data?c4src=home
0 · Reply
MakeSomeMoneyToday
MakeSomeMoneyToday Jun. 24 at 5:52 PM
$NVNO https://vascularspecialistonline.com/two-year-data-show-continued-clinical-improvement-with-venovalve/
0 · Reply
ELONandTRUMP
ELONandTRUMP Jun. 24 at 5:19 PM
$NVNO BERMAN CAN YOU PLEASE UPDATE US ON WTF IS GOING ON IN YOUR COMPANY OMG.
0 · Reply
Liverpool13
Liverpool13 Jun. 23 at 3:33 PM
$NVNO love me some sub $4 dip buying. Thank you
0 · Reply
ELONandTRUMP
ELONandTRUMP Jun. 23 at 2:28 PM
$NVNO im losing brain cells everyday.
0 · Reply
AncientIrmese
AncientIrmese Jun. 22 at 6:17 PM
$NVNO Interesting
0 · Reply
FelixH86
FelixH86 Jun. 21 at 10:47 AM
$NVNO is the stock a good investment?...opinions?..
1 · Reply
ELONandTRUMP
ELONandTRUMP Jun. 21 at 3:18 AM
$NVNO
0 · Reply
SANTORINI
SANTORINI Jun. 20 at 9:40 PM
$NVNO why the drop after hours
0 · Reply
The_Giggly_Hyena
The_Giggly_Hyena Jun. 20 at 6:17 PM
$NVNO The real party doesn’t kick off until July 1st, so keep your party hats on standby.
1 · Reply
ELONandTRUMP
ELONandTRUMP Jun. 20 at 5:27 PM
$NVNO Berman is a idiot
2 · Reply
Mooovingonup
Mooovingonup Jun. 20 at 5:03 PM
$NVNO if there is another below market raise coming, I might go postal
1 · Reply